INS and Hypoglycemia: After 12 months, their HbA1c levels significantly dropped to 5.7% ± 0.4%, fasting C-peptide levels increased to a mean of 1.05 ± 0.40 ng/mL, TIR according to CGM was 89% ± 3% with a 64% reduction in total insulin dose, minor weight loss, and no episodes of severe hypoglycemia, DKA, or other serious side effects after dose stabilization.30